ULTI Ultimovacs

Ultimovacs ASA: Mandatory notification of trade by primary insider

Ultimovacs ASA: Mandatory notification of trade by primary insider

Oslo, March 22, 2024, Board member Henrik Schüssler and primary insider in Ultimovacs ASA, has today through FireH AS bought 50,000 shares in the company at a price of NOK 6.398 per share. Following this transaction, Henrik Schüssler through FireH AS holds 80,900 shares in Ultimovacs ASA.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.



 

Attachment



EN
22/03/2024

Underlying

ULTIUltimovacs

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ultimovacs

 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs Announces Poster Presentation at the 2024 American Society ...

Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting   NON-REGULATORY PRESS RELEASE Oslo, April 24, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces that the data from the Phase II clinical trial INITIUM (), will be presented in a poster session at the 2024 ASCO Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, IL & Online. INITIUM is an Ultimovacs-sponsored randomized, comparative, multi...

April 24, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA – Annual General Meeting held on April 18, 2024

Ultimovacs ASA – Annual General Meeting held on April 18, 2024 Oslo, April 18, 2023: Ultimovacs ASA held its annual general meeting today April 18, 2024. All the matters on the agenda were approved. The following board members were re-elected for a period of one year, and the Board of Directors will consist of the following persons: Jónas Einarsson, Chair of the BoardHenrik Schüssler, board member Kari Grønås, board member Ketil Fjerdingen, deputy board member The Nomination Committee will consist of the following persons until the Annual General Meeting in 2025: Ole Kristian Hjelstue...

April 18, 2024 1 EN
Sean Conroy
  • Sean Conroy
ULTI ULTIMOVACS

Ultimovacs - Steadfast commitment to UV1 progression

Despite the recent setback with the INITIUM trial (first-line treatment of patients with unresectable or metastatic malignant melanoma), Ultimovacs has reinstated its commitment to press on with its clinical development of its cancer vaccine, UV1, across other target indications. The principal near-term focus will be on the anticipated results of Phase II FOCUS (head and neck cancer) and DOVACC (ovarian cancer) trials in Q324 and H125, respectively, and will inform its subsequent strategic direc...

04/18/24 April 18, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs Implements Operational Adjustments to Support Continuous Ad...

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program   Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% Th...

April 16, 2024 1 EN
 PRESS RELEASE
Free
ULTI ULTIMOVACS

Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting

Ultimovacs ASA – Disclosure of voting rights of Annual General Meeting Oslo, April 15, 2024: In connection with the Annual General Meeting of Ultimovacs ASA to be held on April 18, 2024, Jónas Einarsson, Chair of the Board of Directors, has so far received proxy based voting rights without voting instructions for 9,063,854 shares, representing 26.34% of the total voting rights in the company. The proxies are only valid for the Annual General Meeting on April 18, 2024. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading A...

April 15, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch